Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mb07344 SCHEMBL29378732 | 1.00 | THRB (1.00) | THRBTHRA | |
| SCHEMBL13946957 | 0.92 | THRB (0.85) | THRBTHRA | |
| SCHEMBL3160842 | 0.92 | THRB (0.85) | THRBTHRA | |
| SCHEMBL282073 | 0.91 | THRB (1.00) | THRBTHRA | |
| SCHEMBL13703175 | 0.91 | THRB (0.83) | THRBTHRA | |
| SCHEMBL3157077 | 0.90 | THRB (0.81) | THRBTHRA | |
| SCHEMBL28770829 | 0.90 | THRB (0.81) | THRBTHRA | |
| SCHEMBL23791465 | 0.89 | THRB (0.81) | THRBTHRA | |
| SCHEMBL282795 | 0.89 | THRB (1.00) | THRBTHRA | |
| SCHEMBL13044659 | 0.88 | THRB (0.83) | THRBTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 408 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIV OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2026-02-26 | — | — | US | claimed |
| EP-4677084-A1 | MODIFIED SHORT INERFERING NUCLEIC ACID (SINA) MOLECULES AND USES THEREOF | Aligos Therapeutics, Inc. (US) | 2026-01-14 | — | — | EP | claimed |
| US-20250304916-A1 | METHODS AND COMPOSITIONS FOR GENERATING VASCULAR LEPTOMENINGEAL CELLS | TRAILHEAD BIOSYSTEMS INC (US) | 2025-10-02 | — | — | US | claimed |
| US-20250243491-A1 | PNPLA3-TARGETING SHORT INTERFERING RNA (SIRNA) MOLECULES AND USES THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2025-07-31 | — | — | US | claimed |
| EP-4561704-A2 | USE OF GLYCOGEN METABOLISM INHIBITORS FOR THE TREATMENT OF CANCER | The University Of Vermont (US) | 2025-06-04 | — | — | EP | claimed |
| US-20250115872-A1 | GENERATION OF BROWN ADIPOCYTES FROM HUMAN PLURIPOTENT STEM CELLS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2025-04-10 | — | — | US | claimed |
| EP-4473093-A1 | GENERATION OF BROWN ADIPOCYTES FROM HUMAN PLURIPOTENT STEM CELLS | The Brigham and Women's Hospital, Inc. (US) | 2024-12-11 | — | — | EP | claimed |
| CN-118871570-A | Production of brown adipocytes from human pluripotent stem cells | 布里格姆妇女医院 | 2024-10-29 | — | — | CN | claimed |
| WO-2024187038-A1 | MODIFIED SHORT INERFERING NUCLEIC ACID (SINA) MOLECULES AND USES THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2024-09-12 | — | — | WO | claimed |
| WO-2024182446-A2 | PNPLA3-TARGETING SHORT INTERFERING RNA (SIRNA) MOLECULES AND USES THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2024-09-06 | — | — | WO | claimed |
| US-20230255974-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE | 2023-08-17 | — | — | US | claimed |
| WO-2023150555-A1 | GENERATION OF BROWN ADIPOCYTES FROM HUMAN PLURIPOTENT STEM CELLS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2023-08-10 | — | — | WO | claimed |
| CN-116286663-A | In vitro production of human pluripotent stem cell-derived functional beta cells | 詹森生物科技公司 | 2023-06-23 | — | — | CN | claimed |
| CN-115894554-A | Preparation method of phosphonic acid compound | 烟台药物研究所 | 2023-04-04 | — | — | CN | claimed |
| CN-109415693-B | In vitro production of human pluripotent stem cell-derived functional beta cells | 詹森生物科技公司 | 2023-03-21 | — | — | CN | claimed |
| WO-2023039076-A1 | MODIFIED SHORT INTERFERING NUCLEIC ACID (SINA) MOLECULES AND USES THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2023-03-16 | — | — | WO | claimed |
| WO-2023034937-A1 | PNPLA3-TARGETING SHORT INTERFERING RNA (SIRNA) MOLECULES AND USES THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2023-03-09 | — | — | WO | claimed |
| EP-2938723-B1 | DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS INTO PANCREATIC ENDOCRINE CELLS USING HB9 REGULATORS | JANSSEN BIOTECH INC (US) | 2023-02-01 | — | — | EP | claimed |
| EP-4110344-A2 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | The University Of Vermont (US) | 2023-01-04 | — | — | EP | claimed |
| EP-3954759-A1 | USE OF SMALL MOLECULES TO ENHANCE MAFA EXPRESSION IN PANCREATIC ENDOCRINE CELLS | Janssen Biotech, Inc. (US) | 2022-02-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | THRA, THRB, TRHR | THRB 2/4885THRA 1/4885 |
| US-20250243491-A1 | PNPLA3-TARGETING SHORT INTERFERING RNA (SIRNA) MOLECULES AND USES THEREOF | PNPLA2, BCDIN3D, PNP | THRB 2145/4885THRA 2207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.